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perspective was adapted and all costs were adjusted to British pounds in 2014 
value. Results: The mean survival of 311 AML patients was 1.2 years. The aver-
age inpatient costs and standard deviations over a follow-up period ranging from 
7 to 10 years were £38,532 (SD: £44,986), £32,115 (SD: £34,293), and £28,662 (SD: 
£33,298) for bottom-up costing, reference costs, and tariff costings respectively. 
These differences mainly reflect variations in first-line and second-line treatment 
costs (p< 0.001); while during remission, the cost estimates from the three meth-
ods were identical. ConClusions: This study demonstrates that costing methods 
can generate substantially different cost estimates. Hence, decision makers need 
to interpret cost outcomes cautiously, taking account of the assumptions made.
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objeCtives: In economic analyses, the size (volume per vial) of pharmaceutical 
products is usually taken as a fixed quantity. However, whilst the product is in devel-
opment, there is scope for the size to be altered. The objective of this study was to 
examine how product sizes might be optimised for maximum efficiency. Methods: 
Four drugs available in two product sizes were chosen as examples: pemetrexed, 
cetuximab, panitumumab and belimumab. Drug costs per administration were 
estimated based on general population weight and body surface area data from 
the Health Survey for England, using the most efficient combinations of the two 
available vial sizes. The sizes of the two vials were varied simultaneously to identify 
the lowest average costs achievable. Results: Generally, smaller vials were associ-
ated with less wastage and lower costs. Within the size ranges analysed, the cost 
per administration could be reduced by an average of 4.4% (range: 1.12% to 6.39%). 
Over 1 year on treatment, this represents an average potential saving of £1,892 
(range: £120 to £3,289). However, this was associated with an increased number of 
vials per dose. ConClusions: The cost effectiveness of new medicines could be 
enhanced by better planning in the manufacturing process and more efficiently 
sized vials. Costs were generally greater when the large vial was a multiple of the 
smaller vial (which is the case in three of the four example drugs). Non-divisible 
pairs are associated with more precise dosing and less wastage, as a greater number 
of unique quantities can be formed with same numbers of vials. Optimal vial sizing 
could reduce costs for health systems, improving patient access to new medicines 
as a consequence. Increases in the number of vials per dose may impact the time 
and cost of preparation, but additional costs may be offset by savings from reduc-
tions in wastage.
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objeCtives: Cost analysis is an essential component of health economic evalu-
ation. However, cost data are often incomplete due to loss of follow-up or admin-
istrative termination. Ignoring censored data could lead to biased cost results. 
Over the decades, many statistical methods for censored cost data have been pro-
posed. However, studies on method comparison and appropriate application in 
clinical settings are limited. The aim of this study is to compare such methods and 
assess their accuracies in a population of patients with acute myeloid leukaemia 
(AML). Methods: Data were sourced from Haematological Malignancy Research 
Network (www.hmrn.org), an established UK population-based registry, and cost 
data were derived from linked Hospital Episode Statistics (HES). All adults (≥ 18) in 
the network newly diagnosed with AML from September 2004 to August 2007 were 
included (n= 311) and followed until August 2014. Data were censored in 2008, 2010 
and 2012, accordingly cost analyses were undertaken for a minimum follow-up 
period of 1, 3 and 5 years respectively. Seven common methods were used to predict 
mean costs: naïve approaches (full-sample and uncensored cases), Lin’s 2007a, Lin’s 
2007b, Bang and Tsaitis, Lin’s regression and phase-based costing methods. All costs 
were adjusted to British pounds in 2014 value. Results: The true lifetime cost was 
£32,115 per patient. When censored in 2008, the estimate from Bang and Tsaitis 
method was the closest prediction (£30,536). When censored in 2010 and 2012, full-
case naïve and phase-based methods provided more accurate estimates (£31,486 
and £31,501 respectively). ConClusions: The study shows that cost estimations 
vary with the method chosen and the duration of follow-up in the presence of cen-
soring. Compared to the true lifetime cost, the phase-base censoring method with a 
minimum 3-year follow-up would yield the most accurate cost estimation. Further 
work on other cancers are needed to confirm the generalizability of these results.
PRM31
a cOMPaRiSOn Of fat gRafting MethOdS On OPeRating ROOM 
efficiency and cOSt
Gabriel A1, Champaneria MC1, Macarios D2, Griffin L3, Maxwell GP4
1PeaceHealth Medical Group, Vancouver, WA, USA, 2LifeCell, an Acelity company, Bridgewater, NJ, 
USA, 3Acelity, San Antonio, TX, USA, 4Loma Linda University Medical Center, Loma Linda, CA, 
USA
objeCtives: Centrifugation (Cf) is the standard method of fat processing but is 
cumbersome and time consuming, especially when large volumes are processed. A 
new autologous fat processing system (Rv) that incorporates fat harvesting and pro-
cessing in a single unit offers a simple, more efficient system. This study compared 
the efficiency and economics of using Rv with CF in terms of fat grafting and operat-
ing room (OR) costs. Methods: Data were collected over 2 years from consecutive 
breast surgery patients undergoing autologous fat grafting: January to December 
2012 with the Cf method and January to December 2013 with Rv method. The volume 
of fat harvested, volume of fat injected after processing, and time taken to complete 
fat grafting (from harvest to injection) were determined. Standard OR costs ($15-$20 
efficacy and safety profiles for published data on antidepressants fluoxetine and 
venlafaxine vs placebo and is compared to standard SMAA results. Results: The 
results showed that, with a non-informative Dirichlet prior, the posterior mean 
weights for given rankings were similar to the central weight vectors of the standard 
SMAA, so were some other comparable measures such as the rank acceptability 
index and confidence factor ConClusions: The Bayesian SMAA has a number of 
advantages inherited from Bayesian decision analysis. The Bayesian estimates for 
key SMAA measures are similar to those of the standard SMAA. But it offers more 
options and flexibilities than the standard SMAA, and its implementation is easier.
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objeCtives: The objective was to conduct a Bayesian multivariate network meta-
analysis (NMA) to take into account the correlation between three outcome meas-
ures assessing glycaemic control for the monotherapy treatments of type 2 diabetes 
mellitus (T2DM). Methods: A systematic literature review was conducted to iden-
tify relevant randomised clinical trials. The efficacy of T2DM treatments on glycae-
mic control was assessed using the change in HbA1c from baseline, the change in 
fasting plasma glucose (FPG) from baseline or the proportion of patients reaching 
HbA1c < 7%. A Bayesian multivariate NMA accounting for the correlation between 
outcomes was conducted to model these three outcomes simultaneously and results 
were compared to the estimates from the three univariate NMAs. Interpretation of 
results was based on absolute differences/ratios and surface under the cumula-
tive ranking curve (SUCRA). Results: A total of 40 studies were included in the 
analysis, all of them reported results in terms of HbA1c change from baseline, 36 
for FPG and 22 for the proportion of patients reaching HbA1c < 7%. Results for the 
analysis of glycaemic control from the multivariate NMA were overall consistent 
with the three univariate NMAs in terms of ranking of treatments based on the 
SUCRA and point estimates were comparable. Using the multivariate NMA, results 
for the proportion of patients reaching HbA1c < 7% were available for sulfonylureas, 
while no data on sulfonylureas were published for this outcome. Moreover, with the 
multivariate NMA, standard deviations were slightly lower compared to the univari-
ate ones. ConClusions: This multivariate network meta-analysis of treatments 
in T2DM provided more precise estimates than separate univariate NMAs on gly-
caemic control. It enabled estimations of treatment effect for all comparators on all 
endpoints of interest including the ones for which data were not publicly available.
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objeCtives: Indirect Treatment Comparisons (ITC) are used to contrast the effec-
tiveness of two or more treatments, and are usually undertaken in the absence of 
head-to-head information. However, these indirect comparisons are less effective 
in situations where baseline patient characteristics (e.g. age, disease duration) dif-
fer between studies. Any clinically meaningful variation in these characteristics 
between the studies should be adjusted for in the statistical analyses in order to 
arrive at less biased estimates of the treatment differences. At present, many ITCs 
use a comparison of a sponsor’s Individual Patient Data (IPD) with study-level sum-
mary information (typically means and SDs) from their competitors’ studies. Various 
methods currently exist which allow for the matching between studies of the base-
line characteristics means, but crucially not their variances. Methods: We outline 
a novel approach which allows for the matching of both means and variances across 
multiple baseline patient characteristics. Our approach involves fitting higher-order 
polynomials separately to each of the baseline parameters with the aim of estimat-
ing a single weight for each individual patient. The weighted means and variances 
of the IPD are then compared with the (target) summary-level data. Simulation 
is used in order to arrive at the combination of polynomial functions which give 
the ‘best fit’. Results: The method is highlighted with a case study of anti-VEGF 
therapies in the treatment of visual impairment due to diabetic macular edema. Our 
proposed method successfully matches both the means and variances across three 
important predictors of post-baseline changes in visual acuity. ConClusions: The 
ability to match IPD variability with study-level summary variability is critical in 
order to accurately estimate the statistical significance of treatment differences. To 
our knowledge, current comparative effectiveness methods fail to do so - our novel 
approach provides a possible solution to this problem.
ReSeaRch On MethOdS – cost Methods
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objeCtives: Cost is an essential part of health economic evaluation. However, 
no set standard for costing has been suggested/proposed yet, and the impact of 
using different methods remains unclear. The aim of this study is to compare cost 
estimates from different costing methods and assess their impacts. Methods: All 
adults (> 18) newly diagnosed with acute myeloid leukaemia between September 
2004 and August 2007 in the Haematological Malignancy Research Network (HMRN, 
www.hmrn.org, an established UK population-based registry) were included and 
followed until August 2014. Three costing methods were applied to the treatment 
pathways. One was a bottom-up costing, for which cost data were obtained directly 
from treating hospitals; and the other two were top-down costings that used refer-
ence costs and tariffs obtained from UK Hospital Episode Statistics (HES). The NHS 
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associated with long-term mOCS use, and to quantify the cost and QALY burden 
of these events. Methods: A systematic review was undertaken to identify any 
studies reporting adverse event risk due to mOCS treatment. Seventy-two (72) stud-
ies were identified. The review focussed on eight disease outcomes representing 
the bulk of the mOCS cost and QALY burden: type II diabetes, myocardial infarc-
tion, glaucoma, cataract, ulcer, osteoporosis, infection, and stroke. A risk estimate 
for each adverse event was selected, based on the daily dose and mOCS exposure 
that best represented asthma-related mOCS use in Australian clinical practice. 
The excess risk of each complication in patients receiving mOCS, relative to those 
patients not receiving mOCS, was applied to the annual cost and QALY burden of 
each event in the Australian population. The cost and QALY burden attributable to 
mOCS was estimated on a per patient per year basis. Results: The expected annual 
cost of mOCS-related disease outcomes was estimated to be $598.32 per patient 
per year. Each patient treated with mOCS also suffers a QALY loss of 0.0367 per 
year of treatment. These effects are considered reversible once patients stop taking 
mOCS. ConClusions: mOCS are associated with a clear cost and QALY burden 
for patients with severe asthma which is likely underestimated by the approach 
adopted in this study. These results are likely to be useful for economic evaluations 
of new asthma interventions which replace or delay mOCS.
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objeCtives: To compare the cost-effectiveness via progression-free survival (PFS) for 
a new advanced cancer treatment (immuno-therapy A) against two active compara-
tors, both emerging drugs with publications reporting only their comparison against 
best supportive care (BSC) with progression-free survival curves, median survival and 
hazard ratios. Methods: PFS of therapy A compared to BSC could not be represented 
through a single hazard ratio (HR) estimates as progression hazards were obviously 
changing over the study course. Improvements in median PFS in all three studies 
were similar (2.5, 2.6, 2.6 months), while median PFS for BSC in three studies were: 5.0, 
6.7, 4.0 months. This highlighted the need for a meta-analysis to compare therapies. 
Instead of meta-analysing hazard ratios, the Ouwens method was applied to all six 
survival curves: (i) the curves were digitized and fitted to Weibull distributions, (ii) a 
fixed-effects model on shape and scale parameters was developed to deduce adjusted 
survival curves for the two comparators. Results: Two adjusted survival curves for 
comparator therapies were obtained and anchored to the control arm for therapy A. 
The areas under the adjusted PFS curves, with ratios 1.48 and 1.35 in favour of the new 
drug, were introduced in the cost-effectiveness model. ConClusions: The Ouwens 
method of meta-analysing progression-free survival curves was introduced into a 
cost-effectiveness model in advanced cancer. Meta-analysing not just the hazard ratio 
but a 2-parameter fit of the survival curves and adjusting survival curves accordingly 
enabled to build a cost effectiveness model in a situation where comparisons based 
on HR or on median survivals were not feasible.
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objeCtives: Health economic evaluations mostly present decision makers results 
without taking local constraints into account. This might influence the actual use-
fulness of studies and, more importantly, result in suboptimal decisions. Human 
resource constraints have been recently raised as a constraint that is of particular 
importance, especially in low and middle income countries. This review article aims 
to explore to what extent human resource constraints are taken into account in 
economic evaluations. Methods: We conducted systematic literature review via 7 
electronic databases and then consulted some experts for additional relevant articles. 
We searched for articles that investigate economic evaluations and mention human 
resource constraints. Subsequently, these articles were classified based on to what 
extent they addressed human resource constraints. We distinguished the categories 
‘ignoring’, ‘dealing’ and ‘relaxing’ human resource constraints. Furthermore, we clas-
sified studies into modelling studies and studies based on primary data. Results: 
We found 200 articles, approximately. The findings show that 164 articles ignore the 
constraints, accounting for 88 and 76 articles of primary data use and modelling use, 
respectively. Only 32 articles deal with or relax the constraints. Of these articles, 27 
articles focus on the task shifting and the rest of them were distributed to the cat-
egories of dealing and relaxing, almost equally between modelling use and primary 
data use. ConClusions: Many cost effectiveness studies were conducted in settings 
in which human resource constraints are important. Although this is acknowledged, 
human resource constraints are often ignored in health economic evaluations. This 
practice results in biased estimates of the cost-effectiveness of interventions and 
misinforms decision makers. Guidance on how to properly deal with human resource 
constraints in cost-effectiveness analyses is needed.
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objeCtives: Constructing a Markov model can be challenging as available data 
can be limited. In hepatitis C, more complex models that includes F0, F1, F2, F3 
and F4 fibrosis states are required by HTA agencies. However transition probabili-
ties (TP) can only be available for non-cirrhotic to cirrhotic states (simple model). 
Estimating separate TP for Fn to Fn+1 (Fn,n+1) can be challenging as Markov models 
are non-linear. The objective of this study was to estimate Fn,n+1 TP from a single 
non-cirrhotic (F0F3) to cirrhotic (F4) TP. Methods: Results in markov models are 
driven by sum of cycles spent in each state. Thus, the method was built to produce 
per minute for basic surgical procedure, excluding physician costs) were used to 
estimate potential savings. Results: There were a total of 239 cases: Cf= 118 and 
Rv= 121 patients. There were no significant differences between Cf and Rv patients 
in mean age, BMI, smoking status, diabetes, and prior radiation. Mean volume of 
fat harvested (499.5 vs 122.9 ml) and injected (178.9 vs 78.0 mL) were significantly 
higher (p< 0.0001) in the Rv group compared to the Cf group, respectively. Mean time 
to complete fat grafting was significantly shorter in the Rv group compared to the 
Cf group (35.3 vs 89.8 minutes, respectively; p< 0.0001). Mean OR costs with Rv were 
estimated to be $529-$706 vs $1347-$1796 with Cf. After taking into consideration 
the cost of Rv ($470), the potential net savings in mean OR costs were $347-$620 per 
case. ConClusions: The Rv fat processing system decreased operative time, which 
translated into a potential cost savings, and allowed for a larger volume of fat to be 
processed for injection compared to standard centrifugation.
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objeCtives: The NICE methods for technology appraisal require systematic litera-
ture reviews across clinical, cost-effectiveness, cost and resource use and health 
state utility values. These searches are a key component of a manufacturer sub-
mission. Whilst differences in population terms are expected across appraisals, 
this study reviewed search strategies submitted in three recent NICE appraisals 
to assess whether search terms used for methodological filters were consistent. 
The choice of databases searched were also reviewed. Methods: NICE technology 
appraisals were reviewed in reverse chronological order. Manufacturer submissions 
were searched to identify those that reported the search terms used. In order to 
keep the search manageable, a target of three papers was set in the first instance. 
Search terms for the following methodological filters were extracted: quality of 
life, cost and resource use, and cost-effectiveness. Results were compared quali-
tatively to assess the consistencies across search terms. Also extracted were the 
databases searched, presentation of search protocols and any Evidence Review 
Group (ERG) comments. Results: Search terms used for the methodological fil-
ters varied across submissions and similarly the databases searched differed. This 
was noted for all searches, with the comprehensiveness of searches differing across 
the three appraisals. In consideration of the presentation of search protocols, there 
was further variation resulting in lack of transparency. A common approach was 
to run a single search strategy for the cost-effectiveness and cost and resource 
use reviews. ConClusions: From this initial review there appears to be a lack of 
consistency in search terms included and databases searched in NICE technology 
appraisals. Whilst generic search filters are available there appears to be a need to 
drive awareness and application of these search terms. The implication for technol-
ogy appraisals is decision making based on non-optimized evidence bases.
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objeCtives: To review the content of existing resource-use measures with a view 
to conducting a Delphi survey to identify core items that should be included in any 
UK trial-based economic evaluation. bACkgRound: Resource-use measurement 
by patient recall in economic evaluations alongside clinical trials is currently char-
acterised by inconsistency and a lack of validation. A fully validated standardised 
resource-use measure could potentially increase data quality, improve compara-
bility between cost-effectiveness analyses and reduce research burden on health 
economists. Methods: A single version of each instrument designed for use in 
a UK-based study was identified from the Database of Instruments for Resource-
Use Measurement (www.dirum.org). Section headings (‘domains’) and questions 
(‘items’) were extracted verbatim according to a predefined schema. Information 
on the recall period, level of detail, use of skip logic (i.e. a yes/no question designed 
to guide responders past irrelevant questions) and scope (disease-specific or total 
resource use) was also extracted. Items were scrutinised for overlap. Results: In 
excess of 2000 items were extracted from 59 instruments. The range of structures 
used to collect data was extremely wide, and varying levels of information were 
requested about similar items (for example, the number of hospital stays or the 
number of nights spent in hospital). Recall periods varied substantially (sometimes 
within an instrument), and total resource use was more commonly requested than 
disease-specific resource use. Skip logic was employed in over half the instruments 
reviewed. The original items were reduced to a list of 350 following preliminary 
scrutiny for overlap, and further reduced to approximately 60 key items for future 
inclusion in a Delphi survey of health economists.PReliMinARY ConClusions: 
There is substantial variation in the methods used to assess resource use in clini-
cal trials. Further work is in progress to prepare and administer the Delphi survey.
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objeCtives: Maintenance oral corticosteroids (mOCS) are used in the treatment 
of severe asthma where patients have exhausted other available options with-
out achieving acceptable control of their symptoms. However, long-term mOCS 
is associated with the development of a number of serious adverse events. These 
complications cause considerable healthcare costs and quality-adjusted life year 
(QALY) losses. The aim of this study was to establish the excess risk of complications 
